Concepts (198)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endocrinology | 5 | 2024 | 442 | 2.920 |
Why?
|
| Diabetes Mellitus, Type 1 | 21 | 2024 | 3415 | 2.150 |
Why?
|
| Diabetes Mellitus | 5 | 2024 | 5841 | 1.240 |
Why?
|
| Reference Standards | 5 | 2024 | 1003 | 0.870 |
Why?
|
| Standard of Care | 5 | 2024 | 551 | 0.850 |
Why?
|
| Islets of Langerhans Transplantation | 7 | 2022 | 740 | 0.760 |
Why?
|
| Pancreas Transplantation | 2 | 2008 | 197 | 0.520 |
Why?
|
| Societies, Medical | 5 | 2024 | 3905 | 0.480 |
Why?
|
| Dendritic Cells | 1 | 2024 | 2747 | 0.420 |
Why?
|
| Insulin-Secreting Cells | 6 | 2020 | 901 | 0.420 |
Why?
|
| Ferrosoferric Oxide | 1 | 2014 | 348 | 0.420 |
Why?
|
| Kidney Function Tests | 1 | 2014 | 679 | 0.390 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2024 | 12148 | 0.370 |
Why?
|
| Hypoglycemia | 4 | 2024 | 883 | 0.370 |
Why?
|
| Immunosuppressive Agents | 3 | 2019 | 4176 | 0.320 |
Why?
|
| Pancreas | 2 | 2015 | 1691 | 0.310 |
Why?
|
| Islets of Langerhans | 4 | 2013 | 1341 | 0.300 |
Why?
|
| Insulin | 8 | 2024 | 6597 | 0.270 |
Why?
|
| Glycogen Storage Disease Type V | 1 | 2004 | 8 | 0.240 |
Why?
|
| Hyperglycemic Hyperosmolar Nonketotic Coma | 1 | 2004 | 30 | 0.230 |
Why?
|
| Starch | 1 | 2004 | 79 | 0.230 |
Why?
|
| Blood Glucose Self-Monitoring | 2 | 2024 | 467 | 0.230 |
Why?
|
| Sucrose | 1 | 2004 | 158 | 0.220 |
Why?
|
| C-Peptide | 2 | 2024 | 440 | 0.210 |
Why?
|
| Glucagon-Like Peptides | 1 | 2024 | 153 | 0.200 |
Why?
|
| Hypoglycemic Agents | 4 | 2024 | 3085 | 0.200 |
Why?
|
| Lymphocyte Activation | 3 | 2001 | 5485 | 0.200 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2014 | 3359 | 0.190 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2021 | 239 | 0.180 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2001 | 1126 | 0.180 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2021 | 225 | 0.170 |
Why?
|
| Hydroxychloroquine | 1 | 2023 | 426 | 0.170 |
Why?
|
| Venoms | 3 | 2020 | 94 | 0.160 |
Why?
|
| Exercise Tolerance | 1 | 2004 | 836 | 0.160 |
Why?
|
| Transplantation Immunology | 1 | 2001 | 532 | 0.160 |
Why?
|
| Kidney | 1 | 2014 | 7047 | 0.160 |
Why?
|
| Blood Glucose | 10 | 2024 | 6391 | 0.150 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2015 | 36429 | 0.150 |
Why?
|
| Inflammation | 2 | 2015 | 10773 | 0.140 |
Why?
|
| Humans | 35 | 2024 | 761572 | 0.140 |
Why?
|
| Graft Rejection | 3 | 2007 | 4446 | 0.140 |
Why?
|
| Transplantation Tolerance | 1 | 2001 | 605 | 0.130 |
Why?
|
| Double-Blind Method | 3 | 2024 | 12341 | 0.120 |
Why?
|
| Organ Transplantation | 2 | 2022 | 1157 | 0.120 |
Why?
|
| Metabolic Clearance Rate | 1 | 2014 | 361 | 0.110 |
Why?
|
| Tissue and Organ Procurement | 1 | 2022 | 962 | 0.110 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2000 | 1802 | 0.100 |
Why?
|
| Biological Products | 1 | 2021 | 914 | 0.100 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2024 | 3080 | 0.090 |
Why?
|
| Parathyroidectomy | 1 | 2012 | 242 | 0.090 |
Why?
|
| Tissue Distribution | 1 | 2014 | 2264 | 0.090 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2012 | 163 | 0.080 |
Why?
|
| Hypercalcemia | 1 | 2012 | 423 | 0.080 |
Why?
|
| COS Cells | 2 | 2001 | 1130 | 0.080 |
Why?
|
| Comorbidity | 1 | 2024 | 10508 | 0.080 |
Why?
|
| Magnetite Nanoparticles | 1 | 2010 | 318 | 0.080 |
Why?
|
| Dextrans | 1 | 2010 | 574 | 0.080 |
Why?
|
| CHO Cells | 2 | 2001 | 1387 | 0.080 |
Why?
|
| Young Adult | 4 | 2024 | 59255 | 0.080 |
Why?
|
| Adolescent | 5 | 2024 | 88324 | 0.070 |
Why?
|
| Clinical Trials as Topic | 2 | 2019 | 8002 | 0.070 |
Why?
|
| Membrane Proteins | 2 | 2002 | 7858 | 0.070 |
Why?
|
| Cricetinae | 2 | 2001 | 2423 | 0.070 |
Why?
|
| Luminescence | 1 | 2007 | 108 | 0.070 |
Why?
|
| T-Lymphocytes | 2 | 2001 | 10194 | 0.070 |
Why?
|
| Lysine | 1 | 2011 | 993 | 0.070 |
Why?
|
| Thyroid Nodule | 1 | 2014 | 764 | 0.070 |
Why?
|
| Review Literature as Topic | 1 | 2008 | 348 | 0.070 |
Why?
|
| Freund's Adjuvant | 1 | 2006 | 149 | 0.070 |
Why?
|
| Adult | 9 | 2024 | 221203 | 0.070 |
Why?
|
| Microcirculation | 1 | 2010 | 1272 | 0.060 |
Why?
|
| Fluorescent Dyes | 2 | 2011 | 1903 | 0.060 |
Why?
|
| Autoantibodies | 2 | 2023 | 2116 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 5672 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 3 | 2006 | 6214 | 0.060 |
Why?
|
| Cell Transplantation | 1 | 2006 | 472 | 0.060 |
Why?
|
| Female | 13 | 2024 | 392686 | 0.050 |
Why?
|
| Molecular Imaging | 1 | 2010 | 815 | 0.050 |
Why?
|
| Animals | 11 | 2019 | 168467 | 0.050 |
Why?
|
| Insulin Infusion Systems | 1 | 2024 | 217 | 0.050 |
Why?
|
| Glucose | 2 | 2023 | 4346 | 0.050 |
Why?
|
| Celiac Artery | 1 | 2002 | 65 | 0.050 |
Why?
|
| Male | 10 | 2024 | 360842 | 0.050 |
Why?
|
| Peptides | 2 | 2011 | 4358 | 0.050 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2001 | 75 | 0.050 |
Why?
|
| Mice, Inbred NOD | 3 | 2013 | 1827 | 0.050 |
Why?
|
| Receptors, Complement 3b | 1 | 2001 | 135 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2015 | 8633 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2001 | 23447 | 0.050 |
Why?
|
| Monocytes | 1 | 2010 | 2570 | 0.050 |
Why?
|
| Receptors, Complement | 1 | 2001 | 253 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2013 | 4369 | 0.050 |
Why?
|
| Contrast Media | 1 | 2014 | 5311 | 0.050 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 2001 | 284 | 0.050 |
Why?
|
| Amino Acid Sequence | 4 | 2011 | 13446 | 0.050 |
Why?
|
| Middle Aged | 6 | 2024 | 220920 | 0.040 |
Why?
|
| Glucose Tolerance Test | 1 | 2023 | 1178 | 0.040 |
Why?
|
| Antigens, CD | 2 | 2001 | 4001 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2014 | 6241 | 0.040 |
Why?
|
| Immune Sera | 1 | 2000 | 606 | 0.040 |
Why?
|
| Tacrolimus | 1 | 2003 | 733 | 0.040 |
Why?
|
| Spleen | 1 | 2006 | 2295 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2013 | 4580 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 2007 | 1779 | 0.040 |
Why?
|
| Portal Vein | 1 | 2002 | 431 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2004 | 2218 | 0.040 |
Why?
|
| NIH 3T3 Cells | 2 | 2011 | 670 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 5 | 2011 | 22172 | 0.040 |
Why?
|
| Macrophage Activation | 1 | 2002 | 553 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 14666 | 0.040 |
Why?
|
| Receptors, Virus | 1 | 2002 | 640 | 0.040 |
Why?
|
| Models, Biological | 1 | 2014 | 9469 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2013 | 10448 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 20099 | 0.040 |
Why?
|
| Receptors, IgG | 1 | 2000 | 559 | 0.040 |
Why?
|
| Th1 Cells | 1 | 2002 | 1036 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 7391 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2004 | 1410 | 0.030 |
Why?
|
| Sirolimus | 1 | 2003 | 1533 | 0.030 |
Why?
|
| Molecular Sequence Data | 3 | 2011 | 17635 | 0.030 |
Why?
|
| Radiography | 1 | 2007 | 6965 | 0.030 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2002 | 822 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2004 | 4853 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2004 | 4021 | 0.030 |
Why?
|
| Thymus Gland | 1 | 2001 | 1243 | 0.030 |
Why?
|
| Macrophages | 1 | 2010 | 5769 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2021 | 1668 | 0.030 |
Why?
|
| Microscopy, Confocal | 2 | 2011 | 1971 | 0.030 |
Why?
|
| Mice | 7 | 2013 | 81533 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 2000 | 1889 | 0.030 |
Why?
|
| Acute Disease | 1 | 2004 | 7237 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2022 | 1664 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2010 | 22176 | 0.030 |
Why?
|
| Transfection | 1 | 2000 | 5774 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2021 | 2385 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2001 | 2822 | 0.030 |
Why?
|
| Prognosis | 2 | 2021 | 29629 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 10766 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2003 | 4544 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2004 | 10090 | 0.020 |
Why?
|
| Critical Illness | 1 | 2004 | 2723 | 0.020 |
Why?
|
| Receptors, Glucagon | 1 | 2011 | 90 | 0.020 |
Why?
|
| Streptozocin | 1 | 2011 | 194 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2013 | 819 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2007 | 6485 | 0.020 |
Why?
|
| Receptors, Calcium-Sensing | 1 | 2012 | 318 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2000 | 3701 | 0.020 |
Why?
|
| Molecular Probes | 1 | 2010 | 309 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2010 | 2186 | 0.020 |
Why?
|
| Age Factors | 1 | 2004 | 18398 | 0.020 |
Why?
|
| Aged | 2 | 2014 | 169310 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2003 | 9177 | 0.020 |
Why?
|
| Time Factors | 2 | 2005 | 39970 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2010 | 1880 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2011 | 2065 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2000 | 14416 | 0.020 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2010 | 740 | 0.020 |
Why?
|
| Mice, Transgenic | 2 | 2011 | 9541 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2011 | 2645 | 0.010 |
Why?
|
| Child | 2 | 2022 | 80156 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 39107 | 0.010 |
Why?
|
| United States | 2 | 2022 | 72335 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 26127 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2004 | 23996 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2010 | 6132 | 0.010 |
Why?
|
| Binding Sites | 1 | 2011 | 6056 | 0.010 |
Why?
|
| Leukopoiesis | 1 | 2002 | 54 | 0.010 |
Why?
|
| HEK293 Cells | 1 | 2011 | 4280 | 0.010 |
Why?
|
| Internet | 1 | 2014 | 3093 | 0.010 |
Why?
|
| Quality of Life | 1 | 2022 | 13367 | 0.010 |
Why?
|
| Rats, Inbred Lew | 1 | 2002 | 1157 | 0.010 |
Why?
|
| Laparoscopy | 1 | 2011 | 2036 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2004 | 58986 | 0.010 |
Why?
|
| Arginine | 1 | 2002 | 934 | 0.010 |
Why?
|
| Cytokines | 1 | 2013 | 7396 | 0.010 |
Why?
|
| Autoimmunity | 1 | 2006 | 1356 | 0.010 |
Why?
|
| Antibodies | 1 | 2006 | 2418 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2004 | 64684 | 0.010 |
Why?
|
| Apoptosis | 1 | 2013 | 9489 | 0.010 |
Why?
|
| Organ Size | 1 | 2002 | 2254 | 0.010 |
Why?
|
| Regeneration | 1 | 2006 | 1512 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2002 | 4174 | 0.010 |
Why?
|
| Macaca mulatta | 1 | 2002 | 2329 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2024 | 80646 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2011 | 16986 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 15843 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 8528 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2002 | 4807 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 6312 | 0.010 |
Why?
|
| Algorithms | 1 | 2014 | 14032 | 0.010 |
Why?
|
| Graft Survival | 1 | 2002 | 3820 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2002 | 8181 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2006 | 11530 | 0.000 |
Why?
|
| Mutation | 1 | 2012 | 30054 | 0.000 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2006 | 15936 | 0.000 |
Why?
|
| Gene Expression Profiling | 1 | 2002 | 9420 | 0.000 |
Why?
|
| Rats | 1 | 2002 | 23741 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 2003 | 15633 | 0.000 |
Why?
|
Concepts
(198)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(32)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_